Tremelimumab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Tremelimumab: From Oncology Use (Anti-CTLA-4 Immunotherapy) to Diabetic Cataract
One-Sentence Summary
Tremelimumab is an anti-CTLA-4 monoclonal antibody, developed as a cancer immunotherapy (for example, in combination with durvalumab for unresectable hepatocellular carcinoma). The TxGNN model predicts it may be effective for diabetic cataract, but 0 clinical trials and 0 publications currently support this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore licence record (the approved indication text is empty). Reference sources describe use in unresectable hepatocellular carcinoma, in combination with durvalumab |
| Predicted New Indication | Diabetic cataract |
| TxGNN Prediction Score | 98.49% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled records. Based on known information, tremelimumab is an antibody that binds CTLA-4 (CD152), a T-cell checkpoint. Blocking it enhances T-cell activation, which is the basis for its use in cancer.
A plausible mechanistic link to diabetic cataract is not supported by the data compiled for this report. Diabetic cataract is driven by hyperglycaemia-related lens damage (polyol pathway, oxidative stress, glycation), and tremelimumab does not target these pathways. The high TxGNN score appears to reflect similarity within the knowledge graph (many cataract subtypes receive near-identical scores), not independent evidence.
There are also reasons for caution. Immune checkpoint blockade is associated with immune-related ocular adverse events (such as uveitis) and immune-related endocrinopathies, including diabetes. This argues for caution rather than benefit.
Other top-ranked predictions (all L5, all Hold, no trials or literature) include immature, mature, tetanic, craniostenosis, type 2 diabetes-associated, cortical, nuclear senile and senile cataract, and diabetic retinopathy. None has a supported mechanistic rationale.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16845P | IMJUDO Concentrate for Solution for Infusion 20 mg/mL | Infusion, solution concentrate | Not stated in the licence record |
Safety Considerations
- Drug Interactions: The only pharmacology record is the drug's own target, CTLA-4 (CD152), the intended site of action. No drug-drug interactions were listed.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is model-only (L5), with no clinical trials or publications and no plausible mechanistic link between CTLA-4 blockade and lens opacification. The known risk of immune-related ocular and endocrine adverse events makes this a poor repurposing candidate for a non-malignant eye condition.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA (currently missing and blocking safety screening)
- Mechanism of action data
- Preclinical or mechanistic evidence linking CTLA-4 signalling to lens pathology
- A risk-benefit analysis addressing immune-related ocular toxicity, and consideration of whether a systemic biologic is appropriate for a condition that is treated surgically
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.